SeekingAlpha · Aug 20, 2026
Evaxion A/S 2026 Q2 - Results - Earnings Call Presentation
2026-08-20. The following slide deck was published by Evaxion A/S in conjunction with their 2026 Q2 earnings call.
EV
NASDAQ · EVAX
Evaxion Biotech A/S
Healthcare · Biotechnology
$3.31
Up+$0.03 (+0.91%)
Updated Aug 22, 2026, 7:58 PM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 40.36M
- P/E ratio
- -11.8
- Dividend yield
- 0.00%
- 52-week range
- $2.77 – $4.75
- Volume
- 540.83K
- Avg. volume
- 1.63M
Price performance
EVAX price history
1M range · 0 trading sessions · Daily adjusted prices
EVAX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest EVAX news
The latest Smart Investors Daily articles mentioning EVAX.
Stock researchCompany · Overview
EVAX research
Overview
Company profile and research snapshot.
Company profile
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $13.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 24, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 10, 2026 | Jones Trading | Buy | — |
| Mar 9, 2026 | Lake Street | Buy | — |
| Mar 9, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 30, 2025 | Edward Jones | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 20, 2026
Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript
Evaxion A/S (EVAX) Q2 2026 Earnings Call August 20, 2026 8:30 AM EDTCompany ParticipantsHelen Tayton-Martin - Chief Executive OfficerBirgitte Rono - Chief...
Benzinga · Aug 20, 2026
Evaxion Biotech Q2 2026 Earnings Call: Complete Transcript
On Thursday, Evaxion Biotech (NASDAQ:EVAX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Benzinga · Aug 20, 2026
Evaxion Biotech Q2 EPS $(0.01) Beats $(0.31) Estimate
Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.31) by 96.77 percent. This is a 50 percent increase over losses of $(0.02) per share from the
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
